✨
AI Summary
- Alex Aravanis discusses obesity opportunities beyond GLP-1s.
- Moonwalk Biosciences uses adipose-targeted siRNA and AI for drug discovery.
- Company raised $70 million Series B for clinical-stage development.
Guests on This Episode
AP
Alex Aravanis, M.D., Ph.D
1 podcast appearance
More from Life Science Connect
